acute heart failure clinical trials results

beta-blockade continuation versus discontinuation
B-CONVINCED, 2009 NCT00162565).	beta-blockade continuation versus discontinuation BB	acutely decompensated heart failure in patients with LVEF below 40% previously receiving stable beta-blocker therapy	open France
levosimendan versus dobutamine
CASINO, 0	Levosimendan 16 mg/kg þ 0.2 mg/kg/min versus Dobutamine (10 mg/kg/min) and placebo	patients withdecompensatedlow-output HF
LIDO, 2002	Levosimendan versus Dobutamine	patients with low-output heart failure	double-blind Follow-up duration: 24h
SURVIVE, 2007 NCT00348504	Intravenous levosimendan versus intravenous dobutamine	patients hospitalized with acute decompensated heart failure who required inotropic support	double-blind Follow-up duration: 180 days 9 countries
levosimendan versus placebo
REVIVE-I, 2003	levosimendan 0.1–0.2 mg/kg/min versus placebo	patienst with HF andsymptoms at rest
REVIVE II, 2013 NCT00048425	Intravenous Levosimendan versus placebo	patients with decompensated chronic heart failure	double blind Follow-up duration: 5 days
RUSSLAN, 2002	Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h versus placebo	patients with left ventricular failure complicating acute myocardial infarction	double-blind Follow-up duration: 14 days
nesiritide versus control
NSGET (comparative trial), 2000	nesiritide(0.015 and 0.030 microg/kg/min versus usual care	acutely decompensated heart failure requiring invasive monitoring	open Follow-up duration: <5 days US
nesiritide versus dobutamine
PRECEDENT, 2002 NCT00270400	nesiritide(0.015 or 0.03 microg/kg/min) versus Dobutamine (> or =5 microg/kg/min)	Symptomatic, Decompensated CHF	open
nesiritide versus nitroglycerin
VMAC (24h), 2002 NCT00083772	nesiritideinfusion for 24 hours versus nitroglycerin	acutely decompensated heart failure requiring hospitalization
nesiritide versus placebo
ASCEND-HF, 2011 NCT00475852	intravenous nesiritide for 24 hours to 7 days on top of standard therapy versus matching placebo	Patients hospitalized for heart failure (within 24 hours of hospitalization and institution of acute IV therapy for ADHF)	double-blind Follow-up duration: 30 days North America, Europe, Latin America, Asia-Pacific region
BNP-CARDS, 2007 NCT00186329	nesiritide as a 0.01-µg/kg/min infusion for 48 hours versus placebo	acute decompensated heart failure with moderate to severe renal insufficiency	Double blind Follow-up duration: 7 days US
FUSION 2, 2008 NCT00091520	nesiritide (2 µg/kg bolus plus 0.01 µg/kg-per-minute infusion for four to six hours) versus placebo	patients with ACC/AHA stage C/D heart failure with two recent heart-failure hospitalizations, an ejection fraction of less than 40%, and NYHA class 4 symptoms or NYHA class 3 symptoms with creatinine clearance less than 60 mL/min	double-blind Follow-up duration: 12 weeks
NSGET (efficacy trial), 2000	nesiritide(0.015 and 0.030 microg/kg/min versus placebo	acutely decompensated heart failure requiring invasive monitoring
PROACTION, 2003	nesiritidefor at least 12h versus placebo	patients presenting to the ED with acutely decompensated HF and dyspnea at rest or with minimal activity	double-blind Follow-up duration: 30 days USA
VMAC (intravenous neseritide), 2002 NCT00083772	intravenous nesiritidefor 3 hours versus placebo	acutely decompensated heart failure requiring hospitalization	double-blind USA
nesiritide versus standard care
FUSION 1, 2004 NCT00270361	nesiritide 0.005 microg/kg/min or 0.010 microg/kg/min once weekly versus standard care	outpatient with co-morbid advanced heart failure and renal insufficiency	open Follow-up duration: 12 weeks
rolofylline versus placebo
PROTECT, 2010 NCT00328692	daily intravenous rolofylline (30 mg) for up to 3 days versus placebo	patients hospitalized for acute heart failure with impaired renal function	double-blind Follow-up duration: 3 days (60 days)
serelaxin versus placebo
Pre-RELAX-AHF, 2009 NCT00520806	intravenous relaxin for 48 hours: 10µg/kg daily, 30µg/kg daily, 100µg/kg daily, 250µg/kg daily versus placebo	Patients hospitalized with acute heart failure	double blind
RELAX-AHF, 2013 NCT00520806	48-h intravenous infusions of placebo or serelaxin (30 ìg/kg per day) within 16 h from presentation versus placebo (on top stnadard care)	patients admitted to hospital for acute heart failure
tezosentan versus placebo
RITZ 4 importé, 2003	tezosentan (25 mg/h for 1 h, then 50 mg/h for 23 to 47 h) versus placebo	patients with acute heart failure associated with acute coronary syndrome	double-blind Follow-up duration: 72h
RITZ-5, 2003	tezosentan (50 or 100 mg/h) for up to 24 h versus placebo	patients with acute congestive heart failure	double-blind Follow-up duration: 24h
VERITAS I, 2006 NCT00525707	Infusion of tezosentan (5 mg/h for 30 minutes, followed by 1 mg/h for 24 to 72 hours versus placebo	patients with acute heart failure	double-blind Follow-up duration: 7 days Australia, Europe, Israel, and North America.
VERITAS II, 2007 NCT00525707	Tezosentan versus placebo	patients with acute heart failure admitted within the previous 24 hours with persisting dyspnea and a respiratory rate of 24/min or greater	double-blind Follow-up duration: 7 days Australia, Europe, Israel, and North America
tolvaptan versus placebo
EVEREST Clinical Status , 2007 NCT00071331	versus	patients hospitalized with heart failure
EVEREST Outcome, 2007	versus	patients hospitalized with heart failure
tovalpan versus placebo
Udelson, 2007 NCT00043758	tolvaptan 30 mg/day versus placebo	patients with HF and reduced systolic function	double blind Follow-up duration: 1 year